{
    "root": "e0f094fb-01dc-409e-a111-9a2bcc847fd7",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "clindamycin phosphate",
    "value": "20250528",
    "ingredients": [
        {
            "name": "CLINDAMYCIN PHOSPHATE",
            "code": "EH6D7113I8"
        },
        {
            "name": "BENZYL ALCOHOL",
            "code": "LKG8494WBH"
        },
        {
            "name": "CETOSTEARYL ALCOHOL",
            "code": "2DMT128M1S"
        },
        {
            "name": "MINERAL OIL",
            "code": "T5L8T28FGP"
        },
        {
            "name": "POLYSORBATE 60",
            "code": "CAL22UVI4M"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "SORBITAN MONOSTEARATE",
            "code": "NVZ4I0H58X"
        },
        {
            "name": "STEARIC ACID",
            "code": "4ELV7Z65AP"
        }
    ],
    "indications": "clindamycin phosphate vaginal cream 2 % , indicated treatment bacterial vaginosis ( formerly referred haemophilus vaginitis , gardnerella vaginitis , nonspecific vaginitis , corynebacterium vaginitis , anaerobic vaginosis ) . clindamycin phosphate vaginal cream 2 % , used treat non-pregnant women pregnant women second third trimester . ( . ) note : purposes indication , diagnosis bacterial vaginosis usually defined presence homogeneous vaginal discharge ( ) ph greater 4.5 , ( b ) emits `` fishy `` amine odor mixed 10 % koh solution , ( c ) contains clue cells microscopic examination . gram 's stain results consistent diagnosis bacterial vaginosis include ( ) markedly reduced absent lactobacillus morphology , ( b ) predominance gardnerella morphotype , ( c ) absent white blood cells . pathogens commonly associated vulvovaginitis , eg , trichomonas vaginalis , chlamydia trachomatis , n. gonorrhoeae , candida albicans , herpes simplex virus ruled .",
    "contraindications": "recommended dose one applicatorful clindamycin phosphate vaginal cream 2 % , ( 5 grams containing approximately 100 mg clindamycin phosphate ) intravaginally , preferably bedtime , 3 7 consecutive days non-pregnant patients 7 consecutive days pregnant patients . ( . )",
    "warningsAndPrecautions": "clindamycin phosphate vaginal cream 2 % , supplied follows : 40 g tube ( 7 disposable applicators ) ndc 59762-5009-1",
    "adverseReactions": "clindamycin phosphate vaginal cream 2 % , contraindicated individuals history hypersensitivity clindamycin , lincomycin , components vaginal cream . clindamycin phosphate vaginal cream 2 % , also contraindicated individuals history regional enteritis , ulcerative colitis , history `` antibiotic-associated `` colitis .",
    "indications_original": "Clindamycin phosphate vaginal cream 2%, is indicated in the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis). Clindamycin phosphate vaginal cream 2%, can be used to treat non-pregnant women and pregnant women during the second and third trimester. (See CLINICAL STUDIES.)\n                  \n                     NOTE: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a \"fishy\" amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram's stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent Lactobacillus morphology, (b) predominance of Gardnerella morphotype, and (c) absent or few white blood cells.\n                  Other pathogens commonly associated with vulvovaginitis, eg, Trichomonas vaginalis, Chlamydia trachomatis, N. gonorrhoeae, Candida albicans, and Herpes simplex virus should be ruled out.",
    "contraindications_original": "The recommended dose is one applicatorful of clindamycin phosphate vaginal cream 2%, (5 grams containing approximately 100 mg of clindamycin phosphate) intravaginally, preferably at bedtime, for 3 or 7 consecutive days in non-pregnant patients and for 7 consecutive days in pregnant patients. (See CLINICAL STUDIES.)",
    "warningsAndPrecautions_original": "Clindamycin phosphate vaginal cream 2%, is supplied as follows:\n                  \n                     \n                     \n                     \n                        \n                           \n                                40 g tube (with 7 disposable applicators)\n                           \n                           \n                              NDC 59762-5009-1",
    "adverseReactions_original": "Clindamycin phosphate vaginal cream 2%, is contraindicated in individuals with a history of hypersensitivity to clindamycin, lincomycin, or any of the components of this vaginal cream. Clindamycin phosphate vaginal cream 2%, is also contraindicated in individuals with a history of regional enteritis, ulcerative colitis, or a history of \"antibiotic-associated\" colitis."
}